We have located links that may give you full text access.
Comparative Study
Journal Article
Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study.
Surgery for Obesity and Related Diseases 2016 January
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the United States; 85%-95% of the morbidly obese population have NAFLD and 33% have nonalcoholic steatohepatitis. There is a lack of comparative data assessing various bariatric procedures and their effect on NAFLD.
OBJECTIVES: To assess and compare the effects of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) on NAFLD.
SETTING: Academic Center, United States
METHODS: All bariatric cases performed at the authors' institution (an academic center in the United States) between 2005 and 2012 that had both intraoperative and postoperative liver biopsies were included. NAFLD Activity Score (NAS) and fibrosis stages were used to evaluate improvement in liver histology.
RESULTS: Fourteen RYGB and 9 SG patients with liver biopsies were identified. 57% and 73% in each group were female, respectively. P = .2. RYGB patients were older (56.2 ± 8.6 versus 46.3 ± 11.7; P<.05), and had lower initial body mass index (BMI) and higher NAS (51.0 ± 13.0 kg/m(2) versus 72.7 ± 21.0 kg/m(2); P<.05) and (4.4 ± 1.7 versus 2.6 ± 1.6; P<.05), respectively. Prevalence of co-morbidities was comparable between groups. After a mean follow-up of 1.5 years, weight loss percentage was 32% ± 11.8% and 25% ± 6.8% after RYGB and SG, respectively (P value not significant). Percentage of excess weight loss was higher in RYGB patients (69.8% ± 27% versus 37.2% ± 12.3%; P<.05). NAS after RYGB significantly improved in all morphologic characteristics, whereas only steatosis and total NAS improved after SG. Fibrosis state improved in both groups but to a greater degree after RYGB (2.5 ± 1.3 versus .3 ± .6; P< .05).
CONCLUSIONS: There were no significant differences in NAS score decrease after RYGB and SG procedures, although the baseline characteristics of the groups differ. This exploratory data supports the idea of conducting a randomized trial to determine the differential effects of SG and RYGB on NAFLD.
OBJECTIVES: To assess and compare the effects of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) on NAFLD.
SETTING: Academic Center, United States
METHODS: All bariatric cases performed at the authors' institution (an academic center in the United States) between 2005 and 2012 that had both intraoperative and postoperative liver biopsies were included. NAFLD Activity Score (NAS) and fibrosis stages were used to evaluate improvement in liver histology.
RESULTS: Fourteen RYGB and 9 SG patients with liver biopsies were identified. 57% and 73% in each group were female, respectively. P = .2. RYGB patients were older (56.2 ± 8.6 versus 46.3 ± 11.7; P<.05), and had lower initial body mass index (BMI) and higher NAS (51.0 ± 13.0 kg/m(2) versus 72.7 ± 21.0 kg/m(2); P<.05) and (4.4 ± 1.7 versus 2.6 ± 1.6; P<.05), respectively. Prevalence of co-morbidities was comparable between groups. After a mean follow-up of 1.5 years, weight loss percentage was 32% ± 11.8% and 25% ± 6.8% after RYGB and SG, respectively (P value not significant). Percentage of excess weight loss was higher in RYGB patients (69.8% ± 27% versus 37.2% ± 12.3%; P<.05). NAS after RYGB significantly improved in all morphologic characteristics, whereas only steatosis and total NAS improved after SG. Fibrosis state improved in both groups but to a greater degree after RYGB (2.5 ± 1.3 versus .3 ± .6; P< .05).
CONCLUSIONS: There were no significant differences in NAS score decrease after RYGB and SG procedures, although the baseline characteristics of the groups differ. This exploratory data supports the idea of conducting a randomized trial to determine the differential effects of SG and RYGB on NAFLD.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app